O le Heb Therapeutics, o se kamupani biotechnology o loʻo atinaʻeina togafitiga e sosoo ai mo le ogaoga o le toto ma le thrombosis, na faʻaalia i aso nei lona sui taʻitaʻi, HMB-001, o se antibody faʻapitoa e mafai ona togafitia le Glanzmann Thrombasthenia (GT) ma isi faʻafitauli o le toto e le masani ai. . Na tuʻuina atu e le kamupani faʻamatalaga faʻamaonia i luga o le HMB-001 i le 2022 European Association for Haemophilia and Allied Disorders Virtual Congress, na faia ia Fepuari 2-4, 2022.
I le konafesi, na faʻamaonia ai e Heb faʻamatalaga mai suʻesuʻega suʻesuʻeina le faiga o gaioiga mo le HMB-001 i manuki cynomolgus ma faʻataʻitaʻiga ma platelets mai gasegase GT. Ole tui e tasi ole HMB-001 na tu'uina ile in vivo na fa'aalia ai le fa'aputuga fa'alagolago ile fa'atupu VIIa (FVIIa), fa'atasi ai ma le umi o le a'afiaga e lagolagoina i vaiaso ta'itasi ile tasi masina. TLT-1, o se porotini o loʻo maua i luga o le faʻaogaina o platelets i le nofoaga o manuʻa, na faʻamaonia o loʻo i ai i luga o le GT platelets ma le HMB-001 na maua e faʻaleleia atili ai le FVIIa faʻafaigofieina ex vivo GT platelet aggregation i se TLT-1 faʻalagolago. faiga.
O le tu'ufa'atasia o le fa'aputuina ma le fa'atupuina o gaioiga, HMB-001 e fa'atupuina ai le gaioiga a le FVIIa fa'ato'aga i la'asaga e manatu fa'apitoa fa'apitoa e fa'atatau i le poto masani fa'afoma'i fa'atasi ai ma mea fa'aopoopo VIIa (rFVIIa). O le HMB-001 o se antibody bipecific, ma le lima e tasi e fusifusia FVIIa ua uma ona i ai i le toto o le maʻi (endogenous) ae o le isi lima o loʻo fusifusia TLT-1 o loʻo iai i luga o le platelet faʻagaoioia; o lenei mea lelei, aemaise lava, fa'auluina FVIIa i luga o le platelet fa'agaoioia. O le lima e fusifusia ai le FVIIa e puipuia ai le tino mai le talepeina i lalo, faʻateleina le faʻaogaina o loʻo avanoa i totonu o le toto i se tulaga maualuga maualuga atu i luga o ni nai aso. O le fa'amauina fa'aletonu o le FVIIa o lona uiga o lo'o galue pea ma e mafai ona fai sona sao i le fa'atupuina o palaka hemostatic. E ala i le tulituliloaina o platelets ua fa'agaoioia i le nofoaga o fa'aleagaina ga'o ma le maualuga maualuga o le FVIIa (e ala i le TLT-1), e fa'atupuina e le tino ni poloka faufale lelei lelei e fausia ai ni pa'u fa'asoifua maloloina.
I le faiga faapaaga ma Haemnet, o loʻo galulue faʻatasi ma fomaʻi soifua maloloina, tagata gasegase, nuʻu, ma isi paaga e faʻaleleia olaga o tagata e maua i le maʻi toto e ala i suʻesuʻega, aʻoaʻoga, ma fesoʻotaʻiga, o loʻo amataina e Heb suʻesuʻega faʻanatura o tagata mamaʻi ma GT i le amataga o le 2022 i le sili atu. malamalama i le tele o taimi ma ituaiga o toto, numera o tagata e a'afia, fesuiaiga o fa'ama'i, ma a'afiaga i le olaga ma le olaga atoa.
O le a amata e le Hemab le Vaega 1/2 faʻataʻitaʻiga faʻataʻitaʻiga i tagata mamaʻi ma GT i le faaiuga o le 2022 e iloilo ai le saogalemu ma le aoga o le HMB-001, muamua i le galulue faʻatasi ma le taʻitaʻia UK Phase 1 falemaʻi suʻesuʻe, Richmond Pharmacology Ltd.
OA MEA E AVEA MAI LENEI TUSI:
- I le faiga faapaaga ma Haemnet, o loʻo galulue faʻatasi ma fomaʻi soifua maloloina, tagata gasegase, nuʻu, ma isi paaga e faʻaleleia olaga o tagata e maua i le maʻi toto e ala i suʻesuʻega, aʻoaʻoga, ma fesoʻotaʻiga, o loʻo amataina e Heb suʻesuʻega faʻanatura o tagata mamaʻi ma GT i le amataga o le 2022 i le sili atu. malamalama i le tele o taimi ma ituaiga o toto, numera o tagata e a'afia, fesuiaiga o fa'ama'i, ma a'afiaga i le olaga ma le olaga atoa.
- TLT-1, a protein found on the surface of activated platelets at the site of injury, was confirmed to be present on GT platelets and HMB-001 was found to substantially improve FVIIa facilitated ex vivo GT platelet aggregation in a TLT-1-dependent manner.
- HMB-001 is a bispecific antibody, with one arm binding FVIIa already present in the patient’s bloodstream (endogenous) and the other arm binding TLT-1 present on the surface of the activated platelet.
